FibroGen appoints David DeLucia as CFO effective Dec 16, 2024

KYNTRA BIO, INC.

David DeLucia, previously VP of FP&A and IR, promoted to CFO, succeeding Juan Graham who stepped down Dec 15.
DeLucia has nearly 15 years life sciences finance experience; previously at TherapeuticsMD and JP Morgan Asset Mgmt.
As CFO, DeLucia will oversee finance, treasury, IR; reports to CEO Thane Wettig.
Severance terms include 9 months salary for ordinary termination; 12 months salary plus bonus & equity vesting for CIC termination.
Company highlights advancing FG-3246 ADC and companion diagnostic FG-3180 alongside roxadustat performance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.